As an aside, see 3 Risks That Can Make UnitedHealth Stock Unattractive. Additionally, see: MSFT Stock A Winner In 2026? JNJ ...

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.

Johnson & Johnson (JNJ) shares are in focus after two pipeline updates: a Phase 2b win for nipocalimab in systemic lupus ...

Johnson & Johnson (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter. The pharma company also announced it will spin off ...

Hindsight is always 20/20, and nowhere is this more evident than in the stock market. But that doesn’t stop investors from trying to determine what they would have made if they had actually invested ...

Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter ...

Investing.com-- Johnson & Johnson (NYSE:JNJ) said on Thursday it had struck a deal with the Donald Trump administration to ...

On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with ...